Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
about
The prevalence and cost of unapproved uses of top-selling orphan drugsRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRational Use of Recombinant Factor VIIa in Clinical PracticeSearch strategies to identify reports on "off-label" drug use in EMBASE.Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature reviewRecombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation.Off-label paediatric drug use in an Indonesian community setting.Trends in use and safety of image-guided transthoracic needle biopsies in patients with cancer.Recombinant Activated Factor VII Significantly Reduces Transfusion Requirements in Cardiothoracic Surgery.Patterns of use of hemostatic agents in patients undergoing major surgery.Utilization and safety of sodium hyaluronate-carboxymethylcellulose adhesion barrierQuality and Outcomes of Treatment of Hypercalcemia of Malignancy.The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework.Economics of ICU organization and management.Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomesSafety, Utilization, and Cost of Image-Guided Percutaneous Liver Biopsy Among Cancer Patients.Response to treatment and adverse events associated with use of recombinant activated factor VII in children: a retrospective cohort study.Congenital FVII deficiency and pulmonary embolism: a critical appraisal of all reported cases.Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) - a review of a new treatment paradigmUnifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids.Emergency management of bleeding associated with old and new oral anticoagulants.The truth about road traffic accidents.Retrospective study of rFVIIa, 4-factor PCC, and a rFVIIa and 3-factor PCC combination in improving bleeding outcomes in the warfarin and non-warfarin patient.Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies.Comparison of Fresh-Frozen Plasma, Four-Factor Prothrombin Complex Concentrates, and Recombinant Factor VIIa to Facilitate Procedures in Critically Ill Patients with Coagulopathy from Liver Disease: A Retrospective Cohort Study.Efficacy and Safety of Recombinant Factor VII as Rescue for Severe Perioperative Bleeding in HeartMate II Recipients.Massive bleeding in polytrauma: how can we make progress?The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events.Ethics & evidence in medical debates: the case of recombinant activated factor VII.Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report).Predicting dosing advantages of factor VIIa variants with altered tissue factor-dependent and lipid-dependent activities.Recombinant FVIIa concentrate-associated thrombotic events in congenital bleeding disorders other than hemophilias.No evidence or no alternative? Taking responsibility for off-label prescribing.Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.Cost-Effectiveness Analysis of Plasma Versus Recombinant Factor VIIa for Placing Intracranial Pressure Monitors in Pretransplant Patients With Acute Liver Failure.
P2860
Q21134770-DBD6A5E8-B4D8-4601-B12F-4C9A4F031CDCQ24201292-CE6DBFCD-1119-4E9F-99BF-D2F50865753BQ26829915-2F6C3415-2A78-4495-ADC2-C050CBCAB703Q30532169-9B0CD6F9-ABCC-444D-9B3B-F827B1810A6DQ33754446-4CE147FC-F0A7-4785-9FC0-F6A8FB7D3448Q33756657-9BAF9A95-F5AF-40D3-81BA-0C5AB0B05945Q35605202-1C4AA3BA-7B34-4C9A-BA5D-F6A6D0B9262AQ35625682-28EFBB65-7A26-4E76-B36F-266830DF98EBQ35807333-1B8A62AD-3ED9-41B8-B5BF-053DEAFD20F9Q36137393-D24CA1BC-050C-481B-903A-49623AAB7A48Q36219603-17BB1631-7184-4887-A858-8CB6AEAE6E88Q36338328-41891728-BABB-4983-8733-AB031ADDC25AQ36537350-087FE18A-D2DE-4523-AB43-43ECF46B3CB0Q36879259-CD3BFE0B-8428-4755-9205-3BAE283EF68FQ36907218-16D523F8-2401-4A10-A5F1-24DB6578E66AQ37212257-62125418-09D7-4FFC-8CA9-368D1F2E0F5AQ37649896-5FD4F4E3-FAFD-4A35-BF3A-931BF9B08539Q37983460-054D3B81-C12F-4A21-8101-F63435F0CADCQ37993831-CB379F7A-854F-4D66-B435-F1E3666B768DQ38007933-25CAE92B-2EFE-442C-A022-3A08566AFDA6Q38027479-B87A06D5-0106-4504-9119-4121AC968904Q39401841-F12C487C-9367-4252-89E6-04142F9CEFD6Q39853866-D4842812-54FA-4F3A-9590-0FB542FC126CQ40348207-44E3A1CA-EA05-4877-9185-1C95F606F01AQ40612754-BEF19A6B-490B-4628-A7B4-638D300F8461Q40977906-67AE99B5-55AA-4C86-914A-8CD74394F7D2Q41899675-68B00A05-8F84-4CE4-B689-DA78CC798808Q42791749-844F570E-DD1C-47FA-8450-353B95F8E46CQ44637329-3B3FEFD3-C75E-4E19-AC2A-7BDEFCFCA53DQ45862479-D7A808BF-5DB9-4824-A3E3-9421FD8E2F0CQ45865634-BF786BE4-AE56-4BF3-A955-BFF14ED19B49Q45865806-B08E6D86-E358-4ED2-A757-6AB014DFAD75Q45881838-3BFF93AC-DAEF-4D1F-BE6B-1C5680E02CA3Q48465568-E0ECD209-9C9A-492E-BE27-11D028DB994BQ50866803-845D96D9-3030-4420-8055-1FCA63F3915AQ51101241-2CF39C55-1AB6-4FE4-926C-5A28682C5F44
P2860
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
@ast
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
@en
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records.
@nl
type
label
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
@ast
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
@en
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records.
@nl
prefLabel
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
@ast
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
@en
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records.
@nl
P2860
P1476
Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records
@en
P2093
Randall S Stafford
Veronica Yank
P2860
P304
P356
10.7326/0003-4819-154-8-201104190-00002
P407
P577
2011-04-01T00:00:00Z